• Lung Cancer Trial Trends Show Geographic Concentration

    Apr 23 | Clinical Research News | In research presented this week at the American Association for Cancer Research (AACR) Annual Meeting, trends surfaced showing that between 2020 and 2024, the number of unique sites in the United States where phase I clinical trials for non-small cell lung cancer (NSCLC) were conducted decreased by 44% and became increasingly concentrated at the top 20 highest‑volume clinical trial sites largely located in major cities. More

  • Pistoia Alliance Furthers Research on Using Social Media Listening in Drug Discovery, Clinical Research

    Apr 22 | Clinical Research News | In an expansion of its advocacy work into clinical fields, the Pistoia Alliance has launched new patient research to shape the ethical use of social media listening in drug development. The work is part of its ongoing Social Media Real-World Evidence (RWE) project. More

  • Veristat Discovers a Goldmine of Opportunities in China

    Apr 16 | Clinical Research News | Following an eye-opening experience at China’s largest biotechnology and life sciences event, Veristat is positioning itself as a first mover in accommodating the regulatory needs of multiple Chinese companies eager to enter European and North American markets. The shift comes in response to government policy reforms over the past decade, with purpose-built R&D cities and science parks in more recent years acting as physical accelerators. More

  • Cautious Optimism About FDA’s One Pivotal Trial Policy

    Apr 14 | Clinical Research News | Earlier this year, the U.S. Food and Drug Administration (FDA) made a single pivotal clinical trial the default requirement for getting a medicine to market in lieu of the traditional two-trial mandate. It was a controversial move designed to reduce clinical development costs for drug sponsors, but it comes with the peril of potential project failure if study results aren’t rigorously defensible—or if companies fail to invest heavily in the quality of that single trial using readily accessible tools for data monitoring, artificial intelligence (AI), and biosimulation. More

  • AI in the Clinical Space: What 2030 Looks Like

    Apr 09 | Clinical Research News | Clinical research is entering a phase where “using AI” is no longer the headline, and redesigning clinical operations becomes the real work. Mike Sullivan, head of IT globally for development operations at Bristol Myers Squibb, joins The Scope of Things to discuss a persistent industry problem: clinical insight latency, the long delay between data being generated at sites and meaningful decisions being made by sponsors. More

  • AI Tool Adding Speed and Diversity to Cleveland Clinic Trials

    Apr 08 | Clinical Research News | At Cleveland Clinic, a “medically trained” AI system is patient-finding for clinical trials, eliminating the tedium of manual chart reviews for sponsors and investigators requesting digital assistance. Synapsis AI, a Dyania Health technology, was vetted for the job and initially deployed at Cleveland Clinic’s Taussig Cancer Center and its Heart, Vascular and Thoracic Institute. More

  • Managing Metastatic Cancer: A Matter of Degree

    Apr 07 | Clinical Research News | Cancer recurrence is a significant health issue and a major concern for survivors but could potentially be transformed into a manageable chronic condition with the advent of a magnetic nanoparticle hyperthermia system developed by the Israeli startup New Phase and newly installed at the Mayo Clinic last December. The novel technology uses iron oxide-containing nanoparticles that amass in tumors, which are then heated by an electromagnetic field to destroy them. More

  • Continuous Clinical Trials: History, Hype, and How to Make Them Work

    Apr 03 | Clinical Research News | Food and Drug Administration Commissioner Marty Makary has been signaling a potential change to how clinical trials are conducted. Since assuming the Commissioner role, he has championed "continuous trials"  to accelerate drug development, calling the current phased approach inefficient. More

  • piRNA Blood Test Opens New Pathways for Longevity

    Mar 31 | Clinical Research News | A simple blood test built on a handful of small RNA molecules could reshape how researchers study aging and predict survival. Led by Virginia Byers Kraus, M.D. Ph.D., professor in the departments of medicine, pathology, and orthopedic surgery at Duke University School of Medicine, a team of researchers identified piwi-interacting RNAs (piRNAs) as powerful and potentially causal predictors of mortality in older adults. More

  • Blood Biomarker “Clock” Detects Alzheimer’s Symptoms

    Mar 26 | Clinical Research News | Researchers from the Foundation for the National Institutes of Health, Washington University in St. Louis, the University of California San Francisco, the University of Wisconsin-Madison, and other collaborators found that a plasma biomarker—the ratio of phosphorylated to non-phosphorylated plasma tau at position 217, written %p-tau217—can be used to construct a “clock model” that can predict when Alzheimer’s disease symptoms appear. More
View more articles
 
DXX-Industry-spotlight
SOT

The Scope of Things podcast explores clinical research and its possibilities, promise, and pitfalls. Clinical Research News Senior writer Deborah Borfitz welcomes guests who are visionaries closest to the topics, but who can still see past their piece of the puzzle. Focusing on game-changing trends and out-of-the-box operational approaches in the clinical research field, the Scope of Things podcast is your no-nonsense, insider’s look at clinical research today.

Read More